Orexigen Therapeutics (OREX) Presents Additional NB-302 Contrave Data
More News related to OREX
- Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
- Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Orexigen(R) Therapeutics Schedules November 4, 2009 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2009
- Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced positive secondary findings from the first of four Phase 3 trials of its lead investigational product Contrave(R) (naltrexone sustained release (SR)/bupropion SR). These data were presented in one oral and two poster presentations at the American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans, Louisiana.
The oral presentation highlighted the significant improvements in eating control experienced by patients treated with Contrave versus placebo (p< 0.01), as well as previously reported results on the primary weight loss endpoints and measures of cardiometabolic risk.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
